Dapagliflozin and All-Cause Hospitalizations in Patients With Heart Failure With Preserved Ejection Fraction-Reference-Cited by-同舟云学术

Dapagliflozin and All-Cause Hospitalizations in Patients With Heart Failure With Preserved Ejection Fraction

Published:2023-03 Issue:10 Volume:81 Page:1004-1006
ISSN:0735-1097
Container-title:Journal of the American College of Cardiology
language:en
Short-container-title:Journal of the American College of Cardiology

Author:

Vaduganathan Muthiah,Claggett Brian L.,Jhund Pardeep,Miao Zi Michael,de Boer Rudolf A.^ORCID,Lam Carolyn S.P.,Desai Akshay S.,Bengsston Olof,McMurray John J.V.^ORCID,Solomon Scott D.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference2 articles.

1. Dapagliflozin in heart failure with a mildly reduced or preserved ejection fraction;Solomon;N Engl J Med,2022

2. Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: EMPEROR-Preserved Trial;Packer;Circulation,2021

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of Sacubitril/Valsartan on All-Cause Hospitalizations in Heart Failure;JAMA Cardiology;2024-08-30

2. Dapagliflozin: Improving heart failure outcomes does not necessarily mean increasing costs;Revista Portuguesa de Cardiologia;2024-08

3. Is it worth tying the knot? The lifelong commitment between heart failure patients and pulmonary artery pressure monitoring;European Journal of Heart Failure;2024-05

4. Heart failure and respiratory tract infection: Cause and consequence of acute decompensation?;European Journal of Heart Failure;2024-04

5. Empagliflozin and risk of lower respiratory tract infection in heart failure with mildly reduced and preserved ejection fraction: An EMPEROR‐Preserved analysis;European Journal of Heart Failure;2024-03-04